Trial NCT00626197

View at ClinicalTrials.gov 
Org. Study IDs: ACT4072g
Secondary IDs: WA20500

Last trial update was posted on 2020-12-22

MeSH Interventions

Azathioprine Cyclophosphamide Mycophenolic Acid Ocrelizumab

MeSH Conditions

Lupus Erythematosus, Systemic Lupus Nephritis Nephritis

Other Conditions

Systemic Lupus Erythematosus

Stopping Reasons

Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm.

Limitations And Caveats

The study was terminated early due to an imbalance in serious infections in ocrelizumab-treated participants versus placebo-treated participants. Only 139 of the 381 participants randomized completed the 48 week treatment period.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID